Complete Story


FDA Authorizes Novavax Coronavirus Vaccine

This adds to the COVID-19 arsenal

U.S. regulators Wednesday authorized the nation’s fourth coronavirus vaccine, a shot developed by Novavax, a Maryland biotechnology company that has been a straggler in the vaccine race.

For a relatively small niche of people who want to be vaccinated, but can't or won't take existing vaccines, Wednesday's decision by the Food and Drug Administration (FDA) has been impatiently awaited. Some people are allergic to an ingredient in messenger RNA vaccines or simply prefer the more traditional technology at the core of Novavax’s shot, which is the United States’ first protein-based vaccine.

Still, the late addition of Novavax’s vaccine to the medical arsenal is not expected to have a major impact on the trajectory of the coronavirus. Two-thirds of Americans have received at least their initial series of shots, and doses of other companies’ vaccines are abundantly available.

Please select this link to read the complete article from The Washington Post.

Printer-Friendly Version